FACIT Announces Investment in Propellon Therapeutics

Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development.

Seed funding from FACIT enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.  


FACIT Launches The Prospects Oncology Fund

New evergreen fund to help Ontario discoveries reach seed-stage funding faster.

FACIT announces the launch of The Prospects Oncology Fund, designed to advance early-stage Ontario cancer discoveries by supporting the proof-of-concept studies needed to attract seed-stage investment.


FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation

Financing leverages and strengthens Ontario’s next-generation radiotherapeutics expertise, products.

FACIT and OICR report that Fusion Pharmaceuticals Inc. has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. as the lead investor. Additionally, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT.


Triphase Accelerator Announces New Product Option Deal with Celgene

The new collaboration provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.

Triphase Accelerator Corporation announced a new strategic collaboration with Celgene Corporation, that provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.


Triphase Accelerator Announces Acquisition of its First Compound, Marizomib, by Celgene Corporation

Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma

Triphase Accelerator Announces that Celgene Corporation has acquired the company's assets related to its proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.


FACIT Start-up Turnstone Biologics Closes USD $41M Financing

OrbiMed, Versant-led round continues commercialization success for Turnstone’s cancer therapies

FACIT-created Turnstone Biologics raises USD $41M, one of the largest Series B rounds for a Canadian biotech, attracting blue-chip healthcare investors to accelerate commercialization of proprietary oncolytic viral immunotherapies.


Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic

Triphase will obtain worldwide rights to further develop Catalent's proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform.


Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers

FACIT forms biotechnology company for OICR-discovered first-in-class epigenetic modifiers

The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships.


Privacy Analytics Acquired by IMS Health

Integrating innovative data privacy expertise with a global healthcare information & technology service leader, strengthening and driving Ontario’s digital healthcare security footprint.

The transaction combines Privacy Analytics’ leading edge expertise in health data anonymization and de-identification with IMS Health’s broad range of healthcare information, technology and services solutions.


Triphase Accelerator Corporation Announces Expansion of Collaboration with Celgene

Two New Clinical Trials to Be Initiated for Recurrent and Newly Diagnosed Malignant Gliomas

Triphase is expanding its current collaboration with Celgene in the development of marizomib for the potential treatment of malignant gliomas.


Trillium Therapeutics Acquires Fluorinov Pharma

Combined entity creates strong foundation for leading Canadian immuno-oncology company.

Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.


FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics

Image-guided medicines for hard to treat cancers built using next generation medical isotopes.

FACIT's investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.


FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia

First-in-class epigenetic modifiers discovered by OICR positioned for collaborative development.

FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia.


Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma

Orphan drug designation granted by the FDA recognizes the unique potential of marizomib to benefit patients with malignant glioma.

Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.


FACIT Startup Turnstone Biologics Closes $11M Financing, Secures Additional Capital Commitment, and Adds Strong Management

Completion of a Series A financing round enables appointment of Dr. Sammy Farah as CEO and Dr. Brian Lichty as CTO.

Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy potential.


OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers

Research Collaboration and Option and License Agreement Reach Approximately $450 Million Cdn.

OICR, UHN, Novera Therapeutics collaborate with Johnson & Johnson Innovation to accelerate the development drug candidates for haematological cancers. 


Turnstone Biologics Announces Enrollment in Landmark Oncolytic Vaccine Trial

Marabex™ trial to assess the safety of a novel tumour-targeted oncolytic virus vaccine in patients with advanced solid tumours

Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex™ clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours. 


Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors

Fluorinov Pharma and FACIT announce the appointment of Luke M. Beshar, to Fluorinov's Board of Directors.

Mr. Beshar's appointment strengthens Fluorinov’s leadership team, adding financial and pharmaceutical industry expertise as Fluorinov accelerates its clinical development activities.  


Turnstone Biologics Inc. to Accelerate Clinical and Commercial Translation of Cancer Immunotherapies

FACIT partners with Ontario researchers to create new company.

FACIT and its partners are pleased to announce the formation of Turnstone Biologics Inc., a biotechnology company focussed on developing treatments for cancer that harness the patient’s own immune system.


Roger J Garceau Joins Fluorinov Board, Adds Clinical Expertise to Bromodomain Program and Oncology Pipeline

Fluorinov Pharma and FACIT announce the appointment of Dr. Roger J Garceau, to Fluorinov's Board of Directors.

With extensive experience guiding biotech companies in matters including corporate development and clinical strategy, Dr. Garceau's appointment strengthens Fluorinov’s leadership team and adds significant regulatory expertise as Fluorinov transitions to clinical development. 


Fluorinov Pharma and FACIT Announce Investment in Breakthrough Bromodomain Inhibitors for the Treatment of Cancers

FACIT invests in Fluorinov Pharma's novel anti-cancer bromodomain inhibitors and disruptive potential of its technology platform.

TORONTO, ON (January 07, 2015) – FACIT and Fluorinov Pharma announced today an investment in the development of highly potent inhibitors of key bromodomain targets.


Falcons’ Fortunes – Commercial Pitch Competition for $50,000 in Catalyst Funding

FACIT is planning its Falcons’ Fortunes pitch competition in 2015.

On Wednesday, March 11, 2015, FACIT invites you to pitch your idea to a panel of sharp-eyed yet friendly investors. Hosted by the commercially savvy FACIT Falcons, this event is offering $50,000 in Catalyst Funding to invest in the most promising oncology research idea. 


Xagenic Announces Second Closing of $25.5M Series B Financing

FACIT-supported Xagenic Inc is a chip-based diagnostic screening company.

BDC Capital joined as a new investor and Dion Madsen, Senior Managing Partner at BDC Capital, will join Xagenic’s Board of Directors.


XLV Diagnostics Inc. secures a $3 Million Series A investment

XLV Diagnostics Inc. specializes in low-cost, next-generation digital mammography machines.

XLV, a MaRS Innovation start-up company based in Thunder Bay, closed a $3 million Series A investment round with Boston-based Bernard M. Gordon Charitable Remainder Unitrust.


Fluorinov, FACIT and OICR announce novel candidate drugs

Fluorinov has developed three structurally distinct candidate drugs intended to treat cancer pain and brain cancer-related epilepsy.

The candidate drugs have shown excellent preliminary safety profiles, improved treatment and expect to have fewer sedative side effects.


Fluidigm Completes Acquisition of DVS Sciences

High-parameter single-cell protein analysis platform joins with industry-leading single-cell genomics platforms.

With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms.


Triphase Signs Collaboration and Option Agreement with Celgene Corporation

A Unique Collaboration of Life Science Leaders has formed Triphase Accelerator Corporation to be an Oncology Development Accelerator.

Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products.


OICR and MaRS Innovation announce funding for the development of Cellax™

Funding of $1.5 million will be used to further develop a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.

Cellax™, invented by OICR researchers, is a drug-polymer conjugate based on the proprietary NanoCMC™ technology.


Fluorinov Pharma Inc. develops drug for the treatment of blood cancers

OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers.

OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma.


Xagenic Inc. Raises $10 Million to Advance Commercialization of Breakthrough Screening Technology

OICR-supported Xagenic Inc is a new chip-based diagnostic screening company.

Investors in the Series A round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario Capital Growth Corporation through its Emerging Technologies Fund.